Archives

Use the basic search or click on advanced for more search options.

Advanced Search Basic Search Advanced Search

Publications

Section

Select publication to see the relevant sections.

Publication Date

    E.g., 2018-09-20
    E.g., 2018-09-20

Archive Search

2 results
12:00 AM, Jul 01, 2013  |  BioCentury | Finance

2Q Stock Wrap-Up: If it ain't broke

of Johnson & Johnson (NYSE:JNJ) to discover, develop and commercialize positive allosteric modulators (PAM) of metabotropic glutamate receptor subtype 2
mGluR2) to treat anxiety, schizophrenia and other undisclosed indications. 6/4/13 Aveo Pharmaceuticals Inc. (NASDAQ:AVEO) 62% to …
12:00 AM, May 17, 2010  |  BioCentury | Finance

Regulatory Milestones

front and E4.2 million ($5.4 million) in R&D funding. The positive allosteric modulator (PAM) of metabotropic glutamate receptor subtype 2
mGluR2 ) is in Phase I testing to treat central nervous system (CNS) disorders, including …